RecruitingPhase 3NCT06431776

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Studying Autoimmune pulmonary alveolar proteinosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Savara Inc.
Principal Investigator
Matthias Griese, MD,, MD
Ludwig Maximilians Universität München
Intervention
Molgramostim(drug)
Enrollment
5 enrolled
Eligibility
6-18 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06431776 on ClinicalTrials.gov

Other trials for Autoimmune pulmonary alveolar proteinosis

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune pulmonary alveolar proteinosis

← Back to all trials